Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort
Abstract Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ci...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-12-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-021-00248-9 |
| _version_ | 1818383757437042688 |
|---|---|
| author | Emma Rabinovich Kith Pradhan R. Alejandro Sica Lizamarie Bachier-Rodriguez Ioannis Mantzaris Noah Kornblum Aditi Shastri Kira Gritsman Mendel Goldfinger Amit Verma Ira Braunschweig |
| author_facet | Emma Rabinovich Kith Pradhan R. Alejandro Sica Lizamarie Bachier-Rodriguez Ioannis Mantzaris Noah Kornblum Aditi Shastri Kira Gritsman Mendel Goldfinger Amit Verma Ira Braunschweig |
| author_sort | Emma Rabinovich |
| collection | DOAJ |
| description | Abstract Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel with an overall response rate of 71%. Analysis of various biomarkers identified a significant decrease in overall survival with elevated lactate dehydrogenase, measured both at time of cell infusion and before lymphodepletion. Lactate dehydrogenase was prognostic in a multivariate analysis [HR = 1.47 (1.1–2.0)] and a value of 400 U/L at time of infusion and a value of 440 U/L before lymphodepletion provided the best prognostic cutoffs for overall survival in our cohort. These data demonstrate efficacy of anti-CD19 chimeric antigen receptor T-cell therapy in a diverse inner city population and demonstrate novel lactate dehydrogenase cutoffs as prognostic biomarkers. |
| first_indexed | 2024-12-14T03:11:26Z |
| format | Article |
| id | doaj.art-d6a2fbb6a1074b98af04337008c866f1 |
| institution | Directory Open Access Journal |
| issn | 2162-3619 |
| language | English |
| last_indexed | 2024-12-14T03:11:26Z |
| publishDate | 2021-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj.art-d6a2fbb6a1074b98af04337008c866f12022-12-21T23:19:16ZengBMCExperimental Hematology & Oncology2162-36192021-12-011011410.1186/s40164-021-00248-9Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohortEmma Rabinovich0Kith Pradhan1R. Alejandro Sica2Lizamarie Bachier-Rodriguez3Ioannis Mantzaris4Noah Kornblum5Aditi Shastri6Kira Gritsman7Mendel Goldfinger8Amit Verma9Ira Braunschweig10Department of Oncology, Montefiore Medical CenterDepartment of Oncology, Montefiore Medical CenterDepartment of Oncology, Montefiore Medical CenterDepartment of Oncology, Montefiore Medical CenterDepartment of Oncology, Montefiore Medical CenterDepartment of Oncology, Montefiore Medical CenterDepartment of Oncology, Montefiore Medical CenterDepartment of Oncology, Montefiore Medical CenterDepartment of Oncology, Montefiore Medical CenterDepartment of Oncology, Montefiore Medical CenterDepartment of Oncology, Montefiore Medical CenterAbstract Anti-CD19 chimeric antigen receptor T-cell therapies have shown striking clinical activity in diffuse large B-cell lymphoma but robust biomarkers predictive of responsiveness are still needed. We treated a multi-ethnic cohort of 31 diffuse large B-cell lymphoma patients with axicabtagene ciloleucel with an overall response rate of 71%. Analysis of various biomarkers identified a significant decrease in overall survival with elevated lactate dehydrogenase, measured both at time of cell infusion and before lymphodepletion. Lactate dehydrogenase was prognostic in a multivariate analysis [HR = 1.47 (1.1–2.0)] and a value of 400 U/L at time of infusion and a value of 440 U/L before lymphodepletion provided the best prognostic cutoffs for overall survival in our cohort. These data demonstrate efficacy of anti-CD19 chimeric antigen receptor T-cell therapy in a diverse inner city population and demonstrate novel lactate dehydrogenase cutoffs as prognostic biomarkers.https://doi.org/10.1186/s40164-021-00248-9CAR T-cell therapyDLBCLLDH |
| spellingShingle | Emma Rabinovich Kith Pradhan R. Alejandro Sica Lizamarie Bachier-Rodriguez Ioannis Mantzaris Noah Kornblum Aditi Shastri Kira Gritsman Mendel Goldfinger Amit Verma Ira Braunschweig Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort Experimental Hematology & Oncology CAR T-cell therapy DLBCL LDH |
| title | Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort |
| title_full | Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort |
| title_fullStr | Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort |
| title_full_unstemmed | Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort |
| title_short | Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort |
| title_sort | elevated ldh greater than 400 u l portends poorer overall survival in diffuse large b cell lymphoma patients treated with cd19 car t cell therapy in a real world multi ethnic cohort |
| topic | CAR T-cell therapy DLBCL LDH |
| url | https://doi.org/10.1186/s40164-021-00248-9 |
| work_keys_str_mv | AT emmarabinovich elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort AT kithpradhan elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort AT ralejandrosica elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort AT lizamariebachierrodriguez elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort AT ioannismantzaris elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort AT noahkornblum elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort AT aditishastri elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort AT kiragritsman elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort AT mendelgoldfinger elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort AT amitverma elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort AT irabraunschweig elevatedldhgreaterthan400ulportendspooreroverallsurvivalindiffuselargebcelllymphomapatientstreatedwithcd19cartcelltherapyinarealworldmultiethniccohort |